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New challenges for BRCA testing: a view from the
diagnostic laboratory
Andrew J Wallace*
Increased demand for BRCA testing is placing pressures on diagnostic laboratories to raise their mutation screening capacity and
handle the challenges associated with classifying BRCA sequence variants for clinical signiﬁcance, for example interpretation
of pathogenic mutations or variants of unknown signiﬁcance, accurate determination of large genomic rearrangements and
detection of somatic mutations in DNA extracted from formalin-ﬁxed, parafﬁn-embedded tumour samples. Many diagnostic
laboratories are adopting next-generation sequencing (NGS) technology to increase their screening capacity and reduce
processing time and unit costs. However, migration to NGS introduces complexities arising from choice of components of the
BRCA testing workﬂow, such as NGS platform, enrichment method and bioinformatics analysis process. An efﬁcient, cost-
effective accurate mutation detection strategy and a standardised, systematic approach to the reporting of BRCA test results is
imperative for diagnostic laboratories. This review covers the challenges of BRCA testing from the perspective of a diagnostics
laboratory.
European Journal of Human Genetics (2016) 24, S10–S18; doi:10.1038/ejhg.2016.94
INTRODUCTION
The demand for BRCA testing has steadily increased since the
discovery that women carrying pathogenic BRCA mutations have
elevated lifetime ovarian and breast cancer risks.1–3 In a meta-analysis
of pathogenic BRCA mutation penetrance, carriers of BRCA1 and
BRCA2 pathogenic mutations were shown to have a cumulative risk of
57 and 49%, respectively, for developing breast cancer and 40 and
18%, respectively, for developing ovarian cancer by 70 years of age.1 In
support of this observation, results from a prospective epidemiological
study (EMBRACE) showed carriers of BRCA1 and BRCA2 pathogenic
mutations have a cumulative risk of 60 and 55%, respectively, for
developing breast cancer and 59 and 17%, respectively, for developing
ovarian cancer by 70 years of age.2
A contributory factor to the demand for BRCA testing has been
heightened public awareness of the consequences, costs and prophy-
lactic options surrounding BRCA testing, an issue highlighted by
celebrity publicity.3,4 For women carrying pathogenic BRCA muta-
tions, routine surveillance for breast cancer is recommended from 25
years of age and prophylactic salpingo-oophorectomy is recommended
after 35 years or once childbearing is complete.5,6 Prophylactic
oophorectomies and mastectomies have been shown to reduce cancer
incidence compared with chemoprevention or surveillance.7
The increasing demand for BRCA testing is placing a strain on
diagnostic laboratories, particularly in those offering rapid genetic
testing at the point of diagnosis. For instance, the UK’s National
Institute for Health and Care Excellence recommends fast-track
genetic testing as part of a clinical trial within 4 weeks of a diagnosis
of breast cancer.8 Against this backdrop of rising demand, more
diagnostic laboratories are adopting next-generation sequencing
(NGS) technology for BRCA testing, which offers the potential of
fast, scalable, cost-efﬁcient and comprehensive sequencing. In the 2014
BRCA scheme report from the European Molecular Genetics Quality
Network (EMQN), 19% of laboratories were using NGS for BRCA
testing, an increase from 6% of laboratories from the previous year’s
scheme (Dr S Patton, EMQN Director, personal communication).
The same EQA scheme reports also indicated a reduction in the use of
Sanger sequencing alone for BRCA testing: from 83% down to 75% of
laboratories.
Adopting NGS in the diagnostic laboratory setting is not straight-
forward, as the technology is not simple or homogeneous and many
potential conﬁgurations are possible. Transitioning to NGS also
imposes a signiﬁcant validation overhead for clinical laboratories, as
they are compelled to demonstrate that a new assay is sensitive,
speciﬁc and ﬁt for purpose prior to adoption. This review covers key
considerations with respect to NGS and the speciﬁc challenges relating
to BRCA testing, such as difﬁculties in interpreting complex BRCA-
sequencing data and the issues of testing tumour samples.
BRCA TESTING: AN OVERVIEW
Genetic testing is undertaken in many countries to detect BRCA1 and
BRCA2 sequence variants.6 The selection of candidates appropriate for
testing is typically based on national guidelines or by larger interna-
tional societies.5,8 A blood sample is typically used for these tests;
however, other sample types can be used, for example, buccal
scrape.5,6 Written informed consent should be obtained from all
patients prior to storage or analysis of their sample, and genetic
counselling is standard practice both prior to the decision to test and
at the time results are given to the patient.
Sequence variants in BRCA1 and BRCA2 can be subdivided into
three broad classes: single-nucleotide changes, small insertion or
deletion events (indels) and large genomic rearrangements (LGRs).
Pathogenic BRCA single-nucleotide mutations and small indels are
found widely distributed throughout the coding sequence and con-
served intronic sequences of both genes. Typically, a very broad spread
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of pathogenic mutations is present in populations; however, founder
pathogenic mutations are present at high frequency in some popula-
tions. For example, in the Ashkenazi Jewish population three
founder pathogenic mutations (BRCA1 NM_007294.3: c.68_69
delAG p.(Glu23Valfs*17), BRCA1 NM_007294.3: c.5266dupC
p.(Gln1756Profs*74) and BRCA2 NM_000059.3: c.5946delT
p.(Ser1982Argfs*22)) account for the overwhelming majority of
clinically relevant pathogenic mutations and are observed at relatively
high frequency (~2% in total).9,10 In addition, in Polish breast and
breast-ovarian cancer families, three pathogenic mutations in BRCA1
(NM_007294.3: c.5266dupC, NM_007294.3: c.181T4G p.(Cys61Gly)
and NM_007294.3: c.4034delA) were found to account for the
majority of pathogenic BRCA mutations.11 More recently, three
further pathogenic founder BRCA1 mutations have been observed in
a study of 1164 Polish women with unselected breast cancer
(NM_007294.3: c.3700_3704del p.(Val1234Glnfs*8), NM_007294.3:
c.68_69delAG p.(Glu23Valfs*17) and NM_007294.3: c.5251C4T
p.(Arg1751*)).12
BRCA1 contains a number of Alu sequences,13 which are known to
mediate the occurrence of LGRs. In BRCA1, LGRs have been detected
with varying frequencies among patients with breast or ovarian
cancer.14–24 In a study of 805 Dutch families with a known
predisposition for breast and/or ovarian cancer, those without
identiﬁed pathogenic BRCA1 or BRCA2 mutations by conventional
mutation screening methods (661) were assessed for BRCA1 germline
LGRs.23 A total of 33 families with a deletion or duplication event in
BRCA1 were identiﬁed, representing 27% of the total 121 pathogenic
BRCA1 mutations. In a separate study of unrelated individuals
(n= 3580) with a family history of breast and ovarian cancer or those
with early onset disease (n= 934), a 6 kb BRCA1 exon 13 duplication
event was identiﬁed in 11 families with ancestry links to Northern
Britain.22 BRCA2 contains fewer Alu sequences,25 which may explain
why fewer rearrangements have been reported for this gene. Examples
of BRCA2 LGRs include deletion of exon 2 and an Alu insertion in
exon 3, which occurs with relatively high frequency in those patients
from North and Central Portugal.15,26,27
The interpretation of the results of BRCA1 and BRCA2 screening is
made complex by the signiﬁcant numbers of patients with variants of
unknown clinical signiﬁcance (VUS). VUS are alterations in the DNA
sequence of a gene that have an unknown effect on the function of the
gene product or on the risk of disease.28 They can include variants in
promoter regions, intronic nucleotide changes close to the exon
boundary, small in-frame insertions/deletions and missense/synon-
ymous substitutions where there is no ﬁrm evidence for a deleterious
effect on RNA processing, or protein structure and function. In an
analysis of BRCA1 and BRCA2 sequences from 10 000 individuals,
13% were observed to harbour a VUS.29 However, the frequency of
VUS should be lower in well-characterised populations, as databases of
pathogenic BRCA mutations are updated, allowing reclassiﬁcation of
previous VUS. The ﬁnding of a potential VUS during screening
requires detailed expert interpretation and as many sources of
evidence about a variant should be collated and assessed as possible
before coming to a conclusion that is clinically reported.
BRCA testing is commonly performed by direct (Sanger) DNA
sequencing. This method is considered the ‘gold standard’ of DNA
sequencing; technologically reliable, widely available and a relatively
simple workﬂow. The drawbacks of Sanger sequencing are limited
throughput and lower cost-effectiveness compared with NGS. In
addition, Sanger sequencing cannot detect LGRs, which require
alternative polymerase chain reaction (PCR)-based techniques for
analysis. Quantitative PCR is a viable technique for detecting LGRs;24
however, this is labour intensive for analysis of all BRCA1 and BRCA2
exons. Instead, the most commonly used method for analysing LGRs
is multiplex ligation-dependent probe ampliﬁcation (MLPA), a
technique in which pairs of oligonucleotide probes able to ligate to
each other, bind to adjacent positions at the genomic area of interest
and amplify only if both probes are bound and ligated in a semi-
quantitative manner. Examples of commercially available, research-
use-only (RUO) BRCA testing MLPA probes are P002 for BRCA1 and
P045 for BRCA2 (MRC-Holland, Amsterdam, The Netherlands).
Alternatively, some laboratories have developed custom probes
analogous to the MLPA technique,30 or customised PCR assays to
detect speciﬁc LGRs.27
BRCA testing with NGS technology offers many advantages over
Sanger sequencing, including the potential to detect LGRs in a single
workﬂow, although NGS LGR detection has not been fully established
in the diagnostic setting. Some of the key advantages and disadvan-
tages associated with NGS are summarised in Table 1.
The following section describes the key considerations with respect
to adopting NGS in the diagnostic laboratory.
NEXT-GENERATION SEQUENCING: CHOICE AND COMPLEXITY
The rapid evolution of massively parallel sequencing technology and
NGS platforms is revolutionising the management of inherited
diseases, where traditionally molecular diagnostics have been under-
used due to the issues of cost, time, labour and availability of services.
A number of early clinical studies in BRCA testing have shown that
NGS offers high sensitivity, speciﬁcity and cost-effectiveness compared
with current approaches.35–41
Recently, NGS benchtop platforms have made available gigabase-
scale DNA sequencing with relatively short run times (o24 h), for
example, MiSeq (Illumina, San Diego, CA, USA) and the Ion Torrent
Personal Genome Machine (PGM; Life Technologies, Carlsbad, CA,
USA) (refer to Table 2 for examples of NGS platforms). The potential
of high-volume analytical throughput makes NGS platforms an
increasingly attractive investment for diagnostic laboratories in the
clinical setting. However, the choice of NGS platform is only one
factor to consider in the total NGS workﬂow, which is also dependent
on other components including enrichment methods, sequencing
chemistries and analytical procedures (Figure 1).
The following section describes some of the key considerations with
respect to NGS platforms, chemistries and analysis of data.
PLATFORMS
The MiSeq (Illumina) and Ion Torrent PGM (Life Technologies) are
examples of benchtop NGS platforms. Both operate on the principle
of sequencing-by-synthesis, in which the addition of nucleotide
triphosphates to primed clonal DNA templates are measured. In the
Table 1 Advantages and disadvantages of next-generation
sequencing31–35
Advantages Disadvantages
High throughput
Able to multiplex
Lower cost
Automated analysis
Uses less DNA
Can run in parallel with other
genetic tests
Higher start-up cost
Mutation-positive test may require Sanger
sequencing for conﬁrmation
Complex workﬂow
Dedicated data storage and analysis required
Reduced sensitivity for large insertions/dele-
tions 420 base pairs
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case of the MiSeq, these are ﬂuorescently labelled reversible deoxyr-
ibonucleoside triphosphates (dNTPs) and sequences are optically read
by ﬂuorescence imaging.42 Conversely, the Ion Torrent reads
sequences non-optically through the use of semiconductor sequencing
technology (Thermo Fisher, Waltham, MA, USA), where pH changes
resulting from the addition of dNTPs to the nascent strand are
recorded as voltage changes.43 The rapid pace of NGS platform
development renders any detailed review out-of-date by the time of
publication. Given this, up-to-date online reviews such as the NGS
Field Guide from The Molecular Ecologist are important references
when choosing an NGS platform.44
ENRICHMENT METHODS
In the clinical setting, NGS is typically used for sequencing speciﬁc
genes, such as BRCA1 and BRCA2, or panels of genes rather than for
sequencing entire genomes, as it is far more cost-effective and time-
efﬁcient to target, capture and sequence only the genomic regions of
interest. This has led to the development of numerous enrichment
methods, most commonly based on PCR or hybridisation approaches
(Figure 2).45 It is possible that future decreases in the overall cost for
gene sequencing may result in exome sequencing, with a virtual panel
being a cost-effective mode of delivery.46
PCR is a well-established pre-sequencing enrichment technique,
particularly for use with Sanger sequencing. In the case of NGS,
laboratory-developed long-range PCR methods have been used
successfully with BRCA testing;47 however, to make full use of high-
throughput NGS, a large number of amplicons must be prepared
separately and then combined and sequenced together. This has led to
the development of commercially available multiplex PCR kits that
enrich for a speciﬁc gene or panel of genes in a small number of PCR
ampliﬁcations (Figure 2a). For instance, the CE-IVD BRCA MASTR
assay (Multiplicom, Niel, Belgium) ampliﬁes the coding regions of
BRCA1 and BRCA2 in 93 amplicons in ﬁve multiplex PCR reactions.
Other RUO multiplex kits are available for BRCA1 and BRCA2, such
as the Ion Ampliseq Community Panel (Thermo Fisher) and Gene-
Read DNASeq Gene Panel (Qiagen, Hilden, Germany).
Table 2 Examples of next-generation sequencing platforms as of May 2014
Platform Read length (bp) and mode Run timea (hours) Number of reads (single or paired; millions) Data yield (Gb per run)
Illumina MiSeq v2 chemistryb 2×150 paired ~24 24–30 (paired) 4.5–5.1
Illumina MiSeq v3 chemistryb 2×75 paired ~21 44–50 (paired) 3.3–3.8
Illumina MiSeq v3 chemistryb 2×300 paired ~56 44–50 (paired) 13.2–15.0
Ion Torrent PGM, 316 Chip v2c Up to 200 single 3 2–3 (single) 0.3–0.5
Ion Torrent PGM, 318 Chip v2c Up to 200 single 4.4 4.0–5.5 (single) 0.6–1.0
Ion Torrent PGM, 318 Chip v2c Up to 400 single 7.3 4.0–5.5 (single) 1.2–2.0
Ion Torrent Proton with PI Chipc Up to 200 single 2–4 60–80 (single) Up to 10
Illumina NextSeq 500 (mid output)b 2×150 paired 26 Up to 260 (paired) 32.5–39.0
Illumina HiSeq 2500 (rapid run single ﬂow cell)b 2×150 paired 40d Up to 300 (paired) 75–90
aUpstream preparatory work not taken into consideration.
bwww.illumina.com
cwww.lifetechnologies.com
dRun time based on dual ﬂow cell.
Enrichment
 Long-range PCR
 Multiplex PCR
 Hybridisation
   (on-array or in-solution)
Chemistry
 Sequencing-by-  
   synthesis
 Pyrosequencing
Analysis
 Commercial 
   (e.g. NextGENe)
   and platform 
   (e.g. Torrent Suite)
 Custom 
   (e.g. VarScan 
   and Pindel)
Amplicon
 CE-IVD BRCA 
   MASTR assay 
   (Multiplicom)
 Ion Ampliseq 
   Community Panel
   (Life Technologies)
 GeneRead DNASeq 
   Gene Panel
   (Qiagen)
NGS platform
 MiSeq/HiSeq
  (Illumina)
 Ion Torrent PGM
   (Life Technologies)
Figure 1 Components/complexities to consider in the NGS workﬂow, including the NGS platform, enrichment methods, sequencing chemistries and analytical
procedures.
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Molecular inversion probe (MIP)-based enrichment approaches can
provide greater speciﬁcity over standard PCR-based approaches.45
MIPs consist of a universal spacer region ﬂanked by sequences speciﬁc
to either side of the target region (Figure 2b). Once the MIP anneals to
the target, the gap between the sequences is ﬁlled by a DNA
polymerase and ligase. Genomic DNA is digested, and the target
DNA is PCR-ampliﬁed and sequenced. Although PCR as an NGS
enrichment method is highly sensitive, speciﬁc and reproducible,45 it is
inefﬁcient for NGS of larger genomic targets where other approaches
to target enrichment should be considered.
Hybridisation enrichment methods work on the principle of
selection using probes complementary to DNA in the genomic area
of interest (Figure 2c). On-array capture uses high-density microarrays
containing complementary probes, whereas in-solution capture uses
complementary probes that are then puriﬁed using labelled beads
(Figure 2). The in-solution approach has the advantage of being highly
scalable and does not require additional equipment associated with
processing microarrays. Hybridisation kits are available that target
BRCA1 and BRCA2 speciﬁcally, such as RUO, in-solution capture kits,
HaloPlex and SureSelect (Agilent, Santa Clara, CA, USA). In addition,
Exon 1 Exon 2 Exon 3
Molecular inversion probes = 10,000 exons
Gap-fill 
and ligate
B
B
B
B
B
B
B
BB
B
B
BB
B
Adapter-modified 
shotgun library
 Array capture
Solution 
hybridisation
Bead capture
Hybrid capture >100,000 exons
Uniplex PCR
1 reaction =
1 amplicon
Multiplex PCR
1 reaction =
10 amplicons
RainStorm
1 reaction =
4000 amplicons
Figure 2 Enrichment methods. (a) PCR-based approach. Multiplex PCR kits enrich for a speciﬁc gene or panel of genes in a small number of PCR
ampliﬁcations. (b) Molecular inversion probes consist of amplicons containing a universal spacer region ﬂanked by target-speciﬁc sequences. Genomic DNA
is digested, and the target DNA is PCR-ampliﬁed and sequenced. (c) Hybridisation enrichment methods work on the principle of selection using probes
complementary to DNA in the genomic area of interest either by surface microarray or in solution with labelled beads.45 Reprinted with permission from
Mamanova et al.45
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hybridisation kits are available that include BRCA1 and BRCA2 as part
of a larger panel of genes associated with cancer, such as RUO
TruSight Cancer Sequencing Panel (Illumina), which targets 94 genes,
or NimbleGen Comprehensive Cancer Design (Roche NimbleGen,
Madison, WI, USA), which targets 578 genes. It should be noted that
hybridisation methods, particularly on-array capture methods, can add
additional cost, time and, if the panel of genes is extensive, incidental
ﬁndings to the overall NGS process.
BIOINFORMATICS ANALYSIS AND LABORATORY
INFORMATION MANAGEMENT SYSTEMS
Even benchtop NGS platforms produce large amounts of sequence
data that require bioinformatics analysis to align, variant call and ﬁlter
the data to make them accessible, coherent and comprehensible. Many
options are available for a diagnostic laboratory for analysing NGS
data; however, choosing appropriate software and thorough validation
is crucial in order to obtain accurate and reliable results suitable for
clinical application. Commercially available software include Next-
GENe, CLC Workbench (Qiagen) and those linked to speciﬁc plat-
forms, such as the Torrent Suite Software Plugins (Life Technologies).
Publicly available and open-source bioinformatics software can also be
used to build a custom bioinformatics pipeline. Examples include
Pindel, VarScan, GATK-lite and Samtools. It should be noted
that input from bioinformaticians into an NGS-based diagnosis is
an important consideration for reaching a quality level required for
medical analysis.
Tracking and managing clinical samples through a high-throughput
NGS workﬂow requires a laboratory information management system
(LIMS) that can support NGS, is conﬁgurable and customisable to suit
diagnostic laboratories’ needs and yet ﬂexible to accommodate
changes in testing practice. Numerous commercial systems are
available, some of which are tailored to managing NGS workﬂows
in clinical laboratories, such as Exemplar LIMS (Sapio Sciences,
Baltimore, MD, USA), Clarity LIMS (GenoLogics, Victoria, BC,
Canada) and Sequencing LIMS (Edinburgh Genomics, Edinburgh,
UK). Commercial systems tend to involve high setup costs and can
require extensive conﬁguration and customisation to address speciﬁc
laboratory needs. Open-source solutions are also available, such as
Galaxy LIMS (Tron, Mainz, Germany).
NGS FOR DETECTING LARGE GENOMIC REARRANGEMENTS
An NGS-based strategy offers the potential to screen for point
mutations and LGRs on a single platform and workﬂow. NGS has
been applied to detection of LGRs in DNA from cancers using depth
of coverage and a paired-end mapping whole-genome sequencing
approach.48,49
The ability to detect LGRs in NGS data can be limited by the use of
an enrichment method. PCR enrichment methods are currently
unsuitable for reliable measurement of copy-number variants (CNVs).
Hybridisation NGS enrichment methods do offer the potential to
detect CNVs affecting targeted regions. However, this requires
specialist bioinformatics, and particular problems are encountered in
detection of smaller CNVs; o200 bp where sensitivity is low.50,51
Extensive site-speciﬁc validation in the clinical setting is required
before NGS can be routinely used for comprehensive CNV detection
in a clinical setting for BRCA analysis.
BRCA TESTING FROM TUMOUR SAMPLES
Signiﬁcant frequencies of somatic BRCA1 and BRCA2 pathogenic
mutations have been observed in patients with ovarian cancer.52 There
is growing evidence that tumours with somatically acquired BRCA1 or
BRCA2 pathogenic mutations will respond to drugs that inhibit poly
(ADP-ribose) polymerase (PARP).53–56 Tumour samples, as part
of standard pathology practice, are routinely processed and stored as
formalin-ﬁxed parafﬁn-embedded (FFPE) blocks; this presents a
number of challenges to the diagnostic laboratory. FFPE samples are
typically a variable mix of neoplastic and normal cell tissue (stroma)
and the DNA extracted is often limited in quantity, fragmented and of
poor quality. In addition, DNA extracted from FFPE samples may
contain artefactual sequence alterations arising from formalin cross-
linking and deamination of cytosine nucleotides. These problems can
be mitigated by the use of shorter amplicons, de-crosslinking steps and
treatment with uracil-DNA glycosylase, a DNA repair enzyme, which
has been shown to markedly reduce the number of sequence artefacts
in damaged FFPE DNA when used prior to PCR ampliﬁcation.57,58
The challenges in sequencing FFPE tumour samples are observed in
NGS analysis. In a large-scale, prospective, cohort study of the
incidence of cancer in a population in Victoria, Australia, an initial
pilot phase for the ﬁrst 488 patients established the feasibility of NGS
for proﬁling mutations in tumours.59 Disproportionate levels of C4T/
G4A changes were displayed in the 1–10% allele frequency range,
whereas artefacts were less apparent in the 10–25% allele frequency
range. Importantly, an example of the dangers of mutational artefacts
was shown in one sample, where an activating NRAS p.Gly12Asp
mutation was discovered on ﬁrst screening but not conﬁrmed in the
same DNA specimen by subsequent sequencing of uracil-DNA
glycosylase-treated FFPE DNA or repeat NGS. This highlights the
utility of replicate analysis to conﬁrm the identiﬁcation of mutations.
Despite the limitations imposed by DNA extracted from FFPE
samples, successful sequencing with NGS has been shown.57,60,61 In an
NGS study of ovarian (n= 68) and breast (n= 30) FFPE samples,
DNA was ampliﬁed using a GeneRead DNAseq Targeted Exon
Enrichment Breast Panel (Qiagen) and sequenced using a 2×150 bp
analysis on a MiSeq platform (Illumina).62 The majority of samples
with low DNA yields produced adequate PCR products and sequen-
cing data without any signiﬁcant deterioration in coverage or read
depth until o1 ng of ampliﬁable DNA was added per primer pool
(Figure 3). Among 75 samples with less than optimal DNA input, 32
samples still generated the maximum possible coverage of ~ 97%, and
a further 20 samples generated a coverage of 495% at a minimum
read depth of 100× .62 As the input quantity of DNA diminished,
there were still many samples with 490% coverage depth at 100× ,
although the frequency of samples with low percentage coverage at
100× increased. Signiﬁcant variants were conﬁrmed by Sanger
sequencing. A small number of variants were identiﬁed as potential
artefacts common to FFPE-extracted DNA; however, the majority of
these were in the poor-quality low-input DNA samples with lower
coverage depth and artefacts could be identiﬁed as such by replicate
analysis. The conclusion of this study is that routine analysis of BRCA1
or BRCA2 sequences from FFPE breast and ovarian tumours is
feasible. However, it is important that tumour BRCA screening should
not be substituted for germline BRCA screening in patient groups at
high risk of carrying an inherited pathogenic mutation unless proven
to be at least as sensitive as germline screening at detecting the full
range of inherited pathogenic BRCA1 and BRCA2 mutations.
INTERPRETING BRCA TEST RESULTS: DEALING WITH
VARIANTS OF UNKNOWN CLINICAL SIGNIFICANCE
Because of the size of the BRCA1 and BRCA2 genes and the large
number of screens carried out by diagnostic laboratories, many BRCA
gene VUS have been identiﬁed. One study reported a VUS frequency
rate for BRCA1 and BRCA2 of 13% for 10 000 consecutive
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individuals.29 In certain populations, a higher VUS frequency has been
reported, such as 21% of alterations reported in patients with African–
American ancestry.63 However, initiatives to reclassify BRCA VUS are
likely to reduce this number.64–66 In our experience (St Mary’s
Hospital, Manchester, UK) the rate of BRCA VUS is ~ 8%.
Assessing a BRCA VUS is a complex task (Figure 4), but one that is
greatly assisted by pooling of genetic, clinical and histopathological
information from a world-wide network of laboratories. There are
many data-sharing initiatives aimed at developing sequencing methods
and resources to facilitate BRCA1 and BRCA2 variant classiﬁcation.
Examples include the BRCA Challenge (a joint initiative of the Global
Alliance for Genomics and Health and the Human Variome Project)
and the Evidence-based Network for the Interpretation of Germline
Mutant Alleles (ENIGMA).64,67 There has also been a large-scale
collaboration of the International Society for Gastrointestinal Heredi-
tary Tumours (InSiGHT) to develop, test and apply a standardised
classiﬁcation scheme for mismatch repair gene variants in the setting
of Lynch Syndrome.68 The guidance from ENIGMA, along with peer-
reviewed publications, in silico assessment and information from
mutation databases, including BIC (research.nhgri.nih.gov/bic/),
UMD-BE (www.umd.be), DMudB (www.dmudb.net) and HGMD
(www.hgmd.org), assist a diagnostic laboratory to establish the likely
pathogenicity of a BRCA VUS. Caution should be applied when using
information from public mutation databases because of the varying
levels of curation. After reviewing all of the evidence on variant
classiﬁcation, clinical laboratories are required to provide an opinion
for the purpose of clinical decision-making.
As part of the assessment of a BRCA VUS, it is essential to clearly
and systematically categorise a VUS as to whether it is pathogenic,
neutral or of unknown status. This is a critical task, as the risk of
miscomprehension is high among VUS uneducated genetic counsel-
lors. In a recent survey exploring genetic counsellors’ information
preferences on VUS laboratory reports, a minority of respondents
expressed concerns about awareness of VUS and appropriate medical
recommendations among other health-care professionals.69 The
survey also highlighted that the majority of respondents (243/267
(91%)) reported too little information provided on laboratory VUS
reports, and that additional information would help contextualise the
VUS result for patients. This is supported by a previous survey of
breast cancer genetic counselling practices, where only 63% of
genetic counsellors felt their patients understood the meaning of a
VUS ﬁnding.70 It should be noted however, that a minority of genetic
counsellors believe interpretation of additional information to guide
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panel, as it was the closest measure to the mean amplicon size of all methods being evaluated (GeneRead (Qiagen) V.1: 155 bp (estimated), V.2: 153 bp,
Ion AmpliSeq (Life Technologies) ~197 bp). Figure reproduced under the terms of the Creative Commons Attribution License from Ellison et al.62
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patient medical management could be problematic, as interpretation
was the responsibility of the laboratory conducting the test.69
In 2008, Plon et al71 devised a system of ﬁve classes of variants based
on the degree of likelihood of pathogenicity, alongside recommenda-
tions for clinical management (Table 3). In contrast to an earlier
classiﬁcation system,72 this system subdivided the VUS category by the
addition of ‘likely not pathogenic’ or ‘likely pathogenic’. The ﬁve-class
system provides health-care professionals with consistent classiﬁcation
information and clinical recommendations for each variant class.
In order to assist with the application of this system, standardised data
collection forms for VUS assessment are used by diagnostic
laboratories.
CONCLUSIONS
As demand for BRCA testing increases, diagnostic laboratories will
need to adapt their testing strategies and technologies to deal with the
increased sequencing demand. Adoption of NGS can help meet this
high demand and reduce the overall unit cost and staff time required
for analysis; however, the choice and complexity in adopting NGS
requires considerable thought and coordination of multiple-
interdependent elements. Interpretation of screening results, particu-
larly those of VUS, requires a thorough, systematic assessment, and
consistent, clear reporting is essential for mainstream (non-genetic)
disciplines. It is also important for the diagnostic laboratory to be
aware of the signiﬁcant challenges involved with screening tumour
DNA, particularly in view of the potential utility of PARP inhibitors in
tumours with somatic pathogenic BRCA mutations.
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